Other News To Note

Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, reported results from a preclinical study that the companies said provided evidence that MDV3100, an oral androgen receptor antagonist in clinical development to treat advanced prostate cancer patients, inhibits proliferation of breast cancer cells.